Want to see YARW full AI Analyst Report?
YARW Stock Chart & Stats
$37.70
$3.65(9.68%)
At close: 4:00 PM EDT
$37.70
$3.65(9.68%)
Day’s Range― - ―
52-Week Range$14.00 - $46.97
Previous CloseN/A
Volume15.66K
Average Volume (3M)2.75M
Market Cap
$30.11M
Enterprise Value$0.63
Total Cash (Recent Filing)$24.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.02%
Share Statistics
EPS (TTM)-1209.50
Shares Outstanding859,790
10 Day Avg. Volume3,707,448
30 Day Avg. Volume2,746,500
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.87
P/FCF Ratio-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$57.00Price Target Upside51.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-72.5
Revenue Forecast (FY)$350.00K
Bulls Say, Bears Say
Bulls Say
Near-term Funding From Private FinancingsThe ~$200M in pre-closing private financings meaningfully extends runway for clinical development and reduces imminent refinancing risk. For a clinical-stage biotech, this durable liquidity supports planned Phase 2 activities and partner coordination without immediate dilutive capital raises.
Low Leverage / Minimal DebtEffectively no debt lowers interest and covenant risk, giving management flexibility to fund R&D via equity or partnerships. Low leverage is a lasting structural strength for a cash-burning clinical-stage company because it reduces refinancing exposure during multi-year development timelines.
Advancing Clinical Pipeline And Regulatory ProgressPhase 2 dosing and Fast Track status are durable positives: they demonstrate program advancement, can accelerate regulatory interactions, and increase the value of data readouts. Ongoing partner trials in China diversify evidence generation and support broader global development plans.
Bears Say
Negative Free Cash FlowSustained negative FCF of roughly -$25.7M TTM implies ongoing funding needs beyond the near term. Persistent cash burn relative to negligible revenue creates structural dependence on external financing or partnerships, which can dilute shareholders or constrain program pacing.
Very Small, Declining Revenue And Large LossesTiny and falling revenue alongside extreme operating losses indicate the business is still pre-commercial and heavily R&D driven. Over months the lack of commercial traction and negative margins limit internal funding sources and increase reliance on external capital or successful clinical outcomes.
Potential Dilution From Complex Capital StructureLarge pools of pre-funded warrants and broad share authorization create a structural dilution overhang. Even if not immediately dilutive, exercisable derivatives and the authorized share capacity enable future issuance that can materially dilute equity and affect investor control during multi-year development.
Yarrow Bioscience News
YARW FAQ
What was Yarrow Bioscience’s price range in the past 12 months?
Yarrow Bioscience lowest stock price was $14.00 and its highest was $46.97 in the past 12 months.
What is Yarrow Bioscience’s market cap?
Yarrow Bioscience’s market cap is $30.11M.
When is Yarrow Bioscience’s upcoming earnings report date?
Yarrow Bioscience’s upcoming earnings report date is Aug 19, 2026 which is in 12 days.
How were Yarrow Bioscience’s earnings last quarter?
Yarrow Bioscience released its earnings results on May 07, 2026. The company reported -$0.084 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.084.
Is Yarrow Bioscience overvalued?
According to Wall Street analysts Yarrow Bioscience’s price is currently Undervalued.
Does Yarrow Bioscience pay dividends?
Yarrow Bioscience pays a Notavailable dividend of $0.402 which represents an annual dividend yield of 1.02%. See more information on Yarrow Bioscience dividends here
What is Yarrow Bioscience’s EPS estimate?
Yarrow Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yarrow Bioscience have?
Yarrow Bioscience has 859,790 shares outstanding.
What happened to Yarrow Bioscience’s price movement after its last earnings report?
Yarrow Bioscience reported an EPS of -$0.084 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.582%.
Which hedge fund is a major shareholder of Yarrow Bioscience?
Currently, no hedge funds are holding shares in YARW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yarrow Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.00 (51.19% Upside)
$57.00 (51.19% Upside)
Hedge Fund Trend
Decreased
By 642.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.02%
12-Months-Change
Fundamentals
Return on Equity
1.02%
Trailing 12-Months
Asset Growth
-54.14%
Trailing 12-Months
Company Description
Yarrow Bioscience
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
YARW Stock 12 Month Forecast
Average Price Target
$57.00
▲(51.19% Upside)
Ownership Overview
2.97% Insiders
1.77% Mutual Funds
― Other Institutional Investors
94.64% Public Companies and
Individual Investors